Clinical trials: Primary Lateral Sclerosis
ALS - Amyotrophic Lateral Sclerosis
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded…
- Trial name
- CALM (NCT06649955)
- Testing
- Multi-site direct current stimulation (DCS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- PathMaker Neurosystems Inc.
Cerebral Cortex Dysfunction
Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis
This study will test whether primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) affect parts of the brain responsible for thinking, planning, memory and emotion.
- Trial name
- NCT00334516
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis (ALS)
Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis
Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS yielded promising results; however,it is still…
- Trial name
- PEGASUS (NCT06877143)
- Testing
- 100% of individual calory requirement, 120% of individual calory requirement
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis
Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis
Specific aims: Aim 1. To determine the incidence of hypoventilation in Amyotrophic Lateral Sclerosis (ALS) patients. Aim 2. To identify the clinical characteristics and risk factors associated . Aim 3.
- Trial name
- NCT00958048
- Testing
- non-invasive ventilation
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital
Pure Autonomic Failure, Amyotrophic Lateral Sclerosis
Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)
Anti alfa-3 and alfa-7 ganglionic cholinergic receptors (anti-AChRs) antibodies (Abs) plasma removal by plasmapheresis (1,2) acutely improved dysautonomia symptoms in case reports with Pure Autonomic Failure (PAF) (3).
- Conditions
- Pure Autonomic Failure, Amyotrophic Lateral Sclerosis, Postural Orthostatic Tachycardia Syndrome, Anti-Cholinergic Receptors Antibodies
- Trial name
- DISAUT-AB (NCT04875949)
- Testing
- Immunoabsorption/plasmapheresis procedure
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Istituto Clinico Humanitas
Amyotrophic Lateral Sclerosis
Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS)
Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). One potential mechanism of weight loss in ALS is a disturbance of the mitochondrial complex I which causes an energy deficit in affected…
- Trial name
- KETO-ALS (NCT04820478)
- Testing
- Beta Hydroxybutyrate Ester (KetoneAid KE4)
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- University of Ulm
Locked-in Syndrome, Neuromuscular Diseases
Investigation on the Cortical Communication System
The goal of this clinical trial is to demonstrate communication through a brain implant in people in locked-in state, i.e. people with severe paralysis and communication problems.
- Conditions
- Locked-in Syndrome, Neuromuscular Diseases, Brainstem Stroke, Traumatic Brain Injury
- Trial name
- CortiCom (NCT06207591)
- Testing
- ECoG (electrocorticography) sensing
- Where
- Netherlands
- Volunteers
- 2 people
- Sponsor
- UMC Utrecht
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid
Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis is a uniformly progressive and fatal neurodegenerative disorder for which there is no known cure. In a novel attempt to widen the search for potential therapeutic agents, a NINDS- led cooperative…
- Conditions
- Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00718393
- Volunteers
- 1 people
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis (ALS), Motor Neurone Disease (MND)
Metabolism and Nutrition in MND
Motor neurone disease (MND) is a progressive neurological condition that can affect movement, speech, swallowing and breathing. Weight loss and malnutrition are common in people with MND and may be caused by factors including…
- Trial name
- MET-MND (NCT07851714)
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Amyotrophic Lateral Sclerosis
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.
- Trial name
- NCT05299658
- Testing
- CNMAu8
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Clene Nanomedicine
Amyotrophic Lateral Sclerosis (ALS), Emotional Distress
Resiliency Intervention for Patients With ALS and Their Care-Partners
The purpose of this study is to pilot a resiliency and coping intervention for persons recently diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their primary informal caregivers.
- Trial name
- RT-ALS (NCT06968468)
- Testing
- Resilient Together ALS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Motor Neuron Diseases
Collection of Blood Samples for DNA in Motor Neuron Disease
This study will collect blood samples from patients with primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) to be used for research on genetic causes of motor neuron diseases and other neurological disorders.
- Trial name
- NCT00362362
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT01935518
- Testing
- Fasudil
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects…
- Trial name
- NCT02478450
- Testing
- Q-Cells
- Volunteers
- 30 people
- Sponsor
- Q Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
The Effect of Low-İntensity Combined Exercises in Patients With Early Stage ALS.
The aim of this study is to investigate the effects of low-intensity combined exercises on balance, fatigue and quality of life applied to patients with ALS.
- Trial name
- NCT05716074
- Testing
- Supervised exercise, Home exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University - Cerrahpasa
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Long-Term Evaluation of BIIB067 (Tofersen)
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation.
- Trial name
- NCT03070119
- Testing
- Tofersen
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 139 people
- Sponsor
- Biogen
Muscle Spasticity
Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function
Background: Primary lateral sclerosis (PLS) is a rare disease. It leads to weakness in the muscle of the arms, legs, and face. People with PLS develop muscle stiffness called spasticity.
- Trial name
- NCT02408900
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis, ALS
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support.
- Trial name
- NCT03324399
- Testing
- probiotic
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Avera McKennan Hospital & University Health Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.